Pages that link to "Q36623600"
Jump to navigation
Jump to search
The following pages link to Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors (Q36623600):
Displaying 50 items.
- Current targeted therapies in the treatment of advanced colorectal cancer: a review (Q26740067) (← links)
- Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents (Q26747054) (← links)
- Approaches to modernize the combination drug development paradigm (Q28072074) (← links)
- Pathophysiology of colorectal peritoneal carcinomatosis: Role of the peritoneum (Q28073129) (← links)
- Incidence and management of bevacizumab-related toxicities in colorectal cancer (Q28219069) (← links)
- Neuropilin-1 in human colon cancer: expression, regulation, and role in induction of angiogenesis (Q28263245) (← links)
- From bench to bedside: lessons learned in translating preclinical studies in cancer drug development (Q28533949) (← links)
- ERBB receptors and cancer: the complexity of targeted inhibitors (Q29619520) (← links)
- Longitudinal Tracing of Spontaneous Regression and Anti-angiogenic Response of Individual Microadenomas during Colon Tumorigenesis (Q30641075) (← links)
- Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion. (Q33404538) (← links)
- First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients (Q33441143) (← links)
- Phase 1 study of combination treatment with PTK 787/ZK 222584 and cetuximab for patients with advanced solid tumors: safety, pharmacokinetics, pharmacodynamics analysis (Q33622614) (← links)
- Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study (Q34048813) (← links)
- Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial (Q34050239) (← links)
- AAV-mediated human PEDF inhibits tumor growth and metastasis in murine colorectal peritoneal carcinomatosis model (Q34214323) (← links)
- Understanding molecular mechanisms in peritoneal dissemination of colorectal cancer : future possibilities for personalised treatment by use of biomarkers (Q34348691) (← links)
- Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer (Q34450520) (← links)
- An update on epidermal growth factor receptor inhibitors (Q34457436) (← links)
- Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression (Q34538361) (← links)
- New trends in epidermal growth factor receptor-directed monoclonal antibodies (Q34621577) (← links)
- Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer (Q34781374) (← links)
- Flt-1 regulates vascular endothelial cell migration via a protein tyrosine kinase-7–dependent pathway (Q35030948) (← links)
- The role of receptor tyrosine kinase inhibition in treating gastrointestinal malignancy (Q35094666) (← links)
- Resistance mechanisms of gastrointestinal cancers: why does conventional chemotherapy fail? (Q35139963) (← links)
- New advances on prostate carcinogenesis and therapies: involvement of EGF-EGFR transduction system (Q35149046) (← links)
- Clinical significance of angiogenesis in gastrointestinal cancers: a target for novel prognostic and therapeutic approaches (Q35165648) (← links)
- The efficacy and safety of adding bevacizumab to cetuximab- or panitumumab-based therapy in the treatment of patients with metastatic colorectal cancer (mCRC): a meta-analysis from randomized control trials (Q35173455) (← links)
- Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma. (Q35569799) (← links)
- Cetuximab: in the treatment of metastatic colorectal cancer (Q35629076) (← links)
- Anti-cytokine Ab immune therapy: present status and perspectives (Q35687684) (← links)
- Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis (Q35782469) (← links)
- Colon cancer angiogenesis and antiangiogenic therapy (Q35790787) (← links)
- The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC) (Q35938926) (← links)
- Clinical implications of angiogenesis in cancers (Q36012979) (← links)
- Improving delivery of antineoplastic agents with anti-vascular endothelial growth factor therapy (Q36064914) (← links)
- Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma (Q36119978) (← links)
- Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model (Q36160774) (← links)
- Inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation on tumor-associated endothelial cells leads to treatment of orthotopic human colon cancer in nude mice (Q36259629) (← links)
- Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer (Q36286831) (← links)
- Monoclonal antibody-based targeted therapy in breast cancer: current status and future directions (Q36586901) (← links)
- Anti-VEGF therapy: a new approach to colorectal cancer therapy (Q36636633) (← links)
- Angiopoietin-1 inhibits tumour growth and ascites formation in a murine model of peritoneal carcinomatosis (Q36646244) (← links)
- Versican and vascular endothelial growth factor expression levels in peritoneal metastases from colorectal cancer are associated with survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. (Q36706378) (← links)
- Modification of the primary tumor microenvironment by transforming growth factor alpha-epidermal growth factor receptor signaling promotes metastasis in an orthotopic colon cancer model (Q36734908) (← links)
- Angiogenesis-Related Markers and Prognosis After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Metastatic Colorectal Cancer (Q36762304) (← links)
- Biological therapy update in colorectal cancer (Q36764932) (← links)
- Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer (Q36900261) (← links)
- The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion (Q36907325) (← links)
- EGFR, HER2 and VEGF pathways: validated targets for cancer treatment (Q36947038) (← links)
- Development of antiangiogenic agents for ovarian cancer. (Q37038884) (← links)